BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

December 8, 2014

Primary Completion Date

February 13, 2017

Study Completion Date

February 16, 2017

Conditions
GastroenteritisGastritis
Interventions
DRUG

RHB-102

RHB-102, Bimodal Release Ondansetron Tablets

DRUG

Placebo Oral Tablet

Placebo

Trial Locations (26)

10305

Staten Island University Hospital North, Staten Island

11030

North Shore University Hospital, Manhasset

11040

Cohen's Children's Medical Center of NY, New Hyde Park

Long Island Jewish Medical Center, New Hyde Park

11203

Kings County Hospital, Brooklyn

University Hospital of Brooklyn, Brooklyn

11794

Stony Brook University, Stony Brook

15219

UPMC Mercy, Pittsburgh

15261

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

20037

George Washington University, Washington D.C.

21201

University of Maryland Medical Center, Baltimore

32209

University of Florida Jacksonville, Jacksonville

48202

Henry Ford Health System, Detroit

48235

Wayne State University - Sinai Grace Hospital, Detroit

55415

Hennepin County Medical Center, Minneapolis

63110

Washington University - St. Louis, St Louis

75209

CityDoc Urgent Care, Dallas

77030

Baylor College of Medicine, Houston

78503

McAllen Primary Care, McAllen

91342

Olive View- UCLA Medical Center, Sylmar

93311

Kern Medical Center, Bakersfield

95817

UC Davis, Sacramento

97239

Oregon Health and Science University, Portland

02190

South Shore Hospital, South Weymouth

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

RedHill Biopharma Limited

INDUSTRY

NCT02246439 - BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis | Biotech Hunter | Biotech Hunter